Cognitive impairment in relation to depression, anxiety and virological response in hepatitis C patients in Egypt

Abstract

Cognitive impairment is common in HCV patients and increases significantly after interferon treatment. It is not related to depression or anxiety in HCV patients. Future research should focus on prevention, treatment and outcome of cognitive impairment in HCV patients, particularly those receiving interferon therapy.

Psychometric properties of the Montreal Cognitive Assessment (MoCA) in healthy participants aged 18–70

“…The MoCA was developed to be more sensitive to mild cognitive impairment in geriatric populations than other screeners, like the Mini Mental State Examination (MMSE; Folstein et al 1975), and has been translated into nearly 100 languages. Besides geriatrics, the MoCA is widely used in, for instance, substance use, HIV and hepatitis C (Bassiony et al 2015;Bruijnen et al 2016;Copersino et al 2009;Janssen et al 2015). Although the MoCA has gained wide support, research focussing on its psychometric properties, such as alternate-form-, test-retest-and inter-rater reliability, has yielded mixed findings.…”

Depression and anxiety in patients receiving interferon-alpha: The role of illness perceptions

“…There has been less focus on the development of anxiety. However, a recent study reported 46.6 per cent of patients met criteria for generalized anxiety disorder following 12 weeks of IFN-α treatment (Bassiony et al, 2015). When the incidence of depressive and anxiety symptoms are combined, the cumulative incidence can be as high as 60 per cent (Evon et al, 2008; Fontana, 2000; Kraus et al, 2003).…”

Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review

“…70,71 Cognitive dysfunction has been shown to affect approximately one-third of patients with HCV infection without decompensated cirrhosis. 72 Although neurocognitive impairment has been found in patients infected with HCV and mild liver disease, 73,74 it is more marked in patients with advanced liver fibrosis. 75 References: Depression, 28,39,54,55,42,139 anxiety, 28,39,55,139 lower concentration attention, verbal learning, working memory and executive functions, 55 headache, 49,50,51 insomnia, 39 irritability, 49,50,51 fatigue, 49,51,52,55,139 asthenia, 50 muscular pain, 50,139 abdominal pain, 52 general malaise, 50 adverse reactions of antiviral therapy, 52 stigmatization, 55 feelings of despair, inability to control life and fear.…”